Combined Application of Dexamethasone and Tranexamic Acid to Reduce the Postoperative Inflammatory Response and Improve Functional Outcomes in Total Hip Arthroplasty.
Aged
Anti-Inflammatory Agents
/ administration & dosage
Antifibrinolytic Agents
/ administration & dosage
Arthroplasty, Replacement, Hip
C-Reactive Protein
/ analysis
Dexamethasone
/ administration & dosage
Drug Therapy, Combination
Female
Humans
Inflammation
/ prevention & control
Interleukin-6
/ blood
Male
Middle Aged
Pain Measurement
Postoperative Complications
/ prevention & control
Postoperative Period
Range of Motion, Articular
Tranexamic Acid
/ administration & dosage
Clinical outcomes
Dexamethasone
Total hip arthroplasty
Tranexamic acid
Journal
Orthopaedic surgery
ISSN: 1757-7861
Titre abrégé: Orthop Surg
Pays: Australia
ID NLM: 101501666
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
17
02
2020
accepted:
29
02
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
29
10
2020
Statut:
ppublish
Résumé
To evaluate the efficacy and safety of combined use of tranexamic acid (TXA) and dexamethasone (DEX) for anti-inflammatory and clinical outcomes after total hip arthroplasty (THA). A total of 100 patients were included in this randomized, controlled study. Patients in the TXA + DEX group were administered TXA at a dose of 15 mg/kg, which was repeated 3 h after THA, and received 20 mg DEX. In contrast, patients in the TXA group were administered TXA at a dose of 15 mg/kg, which was repeated at 3 h postoperatively. C-reactive protein (CRP), interleukin-6 (IL-6) and pain levels, incidence of postoperative nausea and vomiting (PONV), total blood loss and transfusion rates, postoperative fatigue, range of motion (ROM), length of hospital stay (LOS), analgesic rescue and antiemetic rescue consumption, and complications were compared in both groups. The CRP and IL-6 levels were lower in the TXA + DEX group than in the TXA group (all P < 0.001) at 24 h, 48 h, and 72 h postoperatively. Patients in the TXA + DEX group had lower pain scores at rest and walking at 24 h postoperatively (all P < 0.001). In the TXA + DEX group, the incidence of PONV was lower (P = 0.005), postoperative fatigue (P < 0.001) was reduced, and analgesia and antiemetic rescue consumption were also reduced. The total blood loss, transfusion rate, LOS and hip ROM were similar in the two groups. There was no thrombosis, infection, or gastrointestinal bleeding in either group. Compared to TXA alone, the combination of TXA + DEX can reduce postoperative inflammatory response, relieve pain, and reduce PONV and fatigue, without increasing the risk of complications. Therefore, the present study suggested that the combination of TXA + DEX is an effective and safe accelerated rehabilitation strategy for patients receiving primary unilateral THA.
Identifiants
pubmed: 32347005
doi: 10.1111/os.12664
pmc: PMC7189035
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antifibrinolytic Agents
0
IL6 protein, human
0
Interleukin-6
0
Tranexamic Acid
6T84R30KC1
Dexamethasone
7S5I7G3JQL
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
582-588Informations de copyright
© 2020 The Authors. Orthopaedic Surgery published by Chinese Orthopaedic Association and John Wiley & Sons Australia, Ltd.
Références
Endocr Rev. 2000 Feb;21(1):55-89
pubmed: 10696570
J Arthroplasty. 2018 May;33(5):1426-1431
pubmed: 29258763
J Bone Joint Surg Am. 2018 Feb 21;100(4):295-304
pubmed: 29462033
Orthop Surg. 2017 Feb;9(1):110-114
pubmed: 28294528
J Bone Joint Surg Am. 2018 Sep 5;100(17):1455-1460
pubmed: 30180053
Knee Surg Sports Traumatol Arthrosc. 2018 May;26(5):1549-1556
pubmed: 28474088
J Arthroplasty. 2017 Aug;32(8):2375-2380
pubmed: 28343823
Ann Surg Oncol. 2017 Aug;24(8):2104-2112
pubmed: 28251379
Acta Orthop. 2013 Aug;84(4):342-7
pubmed: 23799348
Pain Med. 2011 Mar;12(3):387-93
pubmed: 21266004
J Arthroplasty. 2013 Sep;28(8 Suppl):11-7
pubmed: 23937923
Acta Orthop. 2007 Oct;78(5):622-8
pubmed: 17966021
Clin Orthop Relat Res. 2013 Sep;471(9):3010-20
pubmed: 23645340
Bone Joint J. 2017 Nov;99-B(11):1442-1449
pubmed: 29092982
J Orthop Trauma. 2017 Jul;31(7):345-351
pubmed: 28633147
Int J Surg. 2018 Apr;52:149-155
pubmed: 29481989
J Arthroplasty. 2017 Jul;32(7):2191-2198
pubmed: 28285898
J Orthop Surg Res. 2017 Jun 27;12(1):100
pubmed: 28655354
Br J Anaesth. 2011 Feb;106(2):230-8
pubmed: 21131371
Medicine (Baltimore). 2018 Mar;97(13):e0100
pubmed: 29595631
J Arthroplasty. 2015 Dec;30(12):2248-55
pubmed: 26228491
Clin Pharmacol Ther. 1990 Aug;48(2):168-78
pubmed: 2379387
BMC Anesthesiol. 2010 Jun 30;10:11
pubmed: 20591163
J Clin Anesth. 2017 Feb;37:116-122
pubmed: 28235499
J Arthroplasty. 2018 Nov;33(11):3429-3436
pubmed: 30078660
Anesth Essays Res. 2018 Apr-Jun;12(2):313-317
pubmed: 29962589
Clin Orthop Relat Res. 2007 Oct;463:7-12
pubmed: 17960669
Ann Surg. 2016 Jul;264(1):73-80
pubmed: 27275778
J Bone Joint Surg Am. 2006 May;88(5):959-63
pubmed: 16651569
Blood Transfus. 2018 Nov;16(6):490-497
pubmed: 30201083
Mediators Inflamm. 2018 Jun 10;2018:3972104
pubmed: 29983634
Pain. 1993 Nov;55(2):171-81
pubmed: 7906026
Sci Rep. 2016 Aug 31;6:30354
pubmed: 27578313
Ann Diagn Pathol. 2017 Apr;27:83-87
pubmed: 27693325
J Orthop Surg Res. 2018 Jun 18;13(1):149
pubmed: 29914535
J Orthop Res. 2018 May;36(5):1519-1525
pubmed: 29077218